Eric Aboagye is Professor of Cancer Pharmacology & Molecular Imaging and Director of the CRUK-EPSRC-MRC-NIHR Comprehensive Cancer Imaging Centre. He joined the college after a PhD at the CRUK Beatson Laboratories in Glasgow, UK and post-doc fellowship at The Johns Hopkins University & Hospital in Baltimore, USA. His group is interested in the discovery and development of new methods for experimental and clinical cancer molecular imaging. In the past 5 years, the team has invented and translated three novel cancer diagnostics into human application. He has acted as an advisor to GE-Healthcare, GSK, Roche and Novartis.
Professor Aboagye was recipient of the 2009 Sir Mackenzie Davidson Medal and was elected as a Fellow of the Academy of Medical Sciences in 2010. Academy Fellows are elected for outstanding contributions to the advancement of medical science, for innovative application of scientific knowledge or for conspicuous service to healthcare.
Aboagye EO, PET imaging of small animals in anticancer drug development, Molecular Imaging in Biology, Vol:7, Pages:53-58
et al., 2018, Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors., Oncotarget, Vol:9, Pages:27346-27362
et al., 2018, Repeatability of quantitative F-18-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis, European Journal of Nuclear Medicine and Molecular Imaging, Vol:45, ISSN:1619-7070, Pages:951-961
et al., 2018, Depicting changes in tumor biology in response to cetuximab mono- or combination therapy by apoptosis and proliferation imaging using 18F-ICMT-11 and 3'-Deoxy-3'-[18F]Fluorothymidine (18F-FLT) PET., J Nucl Med
et al., 2018, ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment, UK Breast Cancer Research Symposium, AMER ASSOC CANCER RESEARCH, Pages:1156-1166, ISSN:1535-7163